Gland Pharma — 360° view

Gland Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹1,834 crore and net profit of ₹291 crore for the September 2026 quarter.

Gland Pharma (NSE: GLAND) closed at ₹3,331.90 on 20 Nov 2026, up 83.3% over the past year. Its market capitalisation is ₹54,980 crore and it trades at 43.9 times earnings.

Share price
₹3,331.90 (20 Nov 2026)
Market cap
₹54,980 Cr (20 Nov 2026)
P/E
43.88 (20 Nov 2026)
Revenue
₹1,834 Cr (September 2026 quarter)
Net profit
₹291 Cr (September 2026 quarter)
ROCE
15.1% (FY26)
ROE
10.7% (FY26)
Book value
₹648 (FY26)
Dividend yield
0.60% (last 12 months to 20 Nov 2026)
52-week high / low
₹3,429.00 / ₹1,573.60 (20 Nov 2026)
1-year return
83.3% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: GLAND

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.